Navigation Links
DCIS patients overestimate breast cancer risks
Date:2/12/2008

Many women diagnosed with ductal carcinoma in situ (DCIS) have inaccurate perceptions of their breast cancer risks, according to a study published online February 12 in the Journal of the National Cancer Institute.

DCIS is a noninvasive precancer in which abnormal cells are found in the lining of a breast duct. Women with DCIS generally have a favorable prognosisrecurrence rates are low and only about one percent of DCIS patients die from breast cancer. Nonetheless, studies suggest that DCIS patients overestimate their risks of DCIS recurrence and developing invasive breast cancer.

Ann Partridge, M.D., and colleagues at Dana-Farber Cancer Institute in Boston investigated perceived breast cancer risks among women with newly diagnosed DCIS and how these risk perceptions were associated with anxiety and depression. They surveyed nearly 500 newly diagnosed DCIS patients about their quality of life (including depression and anxiety) and their perceived risk of recurrence or invasive breast cancer. The surveys were completed at enrollment in the trial and then again at 9 and 18 months.

At the time of enrollment, 10 percent of patients reported substantial anxiety, and two percent were depressed. Over time, anxiety levels decreased, and depression levels remained low. At enrollment, 54 percent of patients said they believed they were at least moderately likely to develop DCIS again within the next five years and 68 percent believed it was at least moderately likely to happen again at some point in their lifetime. Also, 28 percent of the women believed that it was at least moderately likely that DCIS would spread to other parts of their body. After 18 months, these perceptions had not changed substantially. Higher levels of anxiety were associated with an overestimation of future risks.

Although women with DCIS appear to experience a reasonably favorable overall quality of life, some DCIS survivors may suffer from increa
'/>"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

3

GOOD

Page: 1 2

Related medicine news :

1. Anxiety linked to newly diagnosed DCIS patients overestimation of breast cancer risks
2. Precious Time - Scientists discover how long heart failure patients can expect to live
3. Patients with larger social networks may fare better after an operation
4. A new agent for the treatment of patients with myelodysplastic syndrome; and more
5. Doctors uncertain about approaches to care for heart failure patients, SLU study finds
6. Depression Rarely Discussed With RA Patients
7. Doctor who? Are patients making clinical decisions?
8. Study finds patients with complex fibroadenomas can avoid surgery
9. Allergic-like reactions occur in premedicated patients
10. Gene variant predicts medication response in patients with alcohol dependence
11. Study suggests new therapy for lung disease patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... partners with Cure to support medical research. , ... ... its part to help find a cure for spinal cord injury: ... Catheters to its list of nearly 45,000 products., , ,Cure Medical ... facilitate finding a cure for spinal cord injury, the company donates ...
(Date:12/7/2009)... suffer from more emotional and behavioral difficulties when compared ... struggling the most when a parent is deployed overseas, ... found that having a parent deployed for a longer ... has struggled with emotional problems were important factors associated ... the study published online by the journal Pediatrics ...
(Date:12/6/2009)... from San Antonio Bay ,, SILVER SPRING, Md., ... Administration is advising consumers to avoid eating oysters harvested ... 16 due to reports of norovirus-associated illnesses in some ... which is located on the Gulf of Texas. ... FDA, along with the Centers for Disease Control and ...
(Date:12/6/2009)... from the Medical College of Wisconsin, in Milwaukee, found ... other sickle cell disease complications in children. Barriers to ... patients were also identified. The study led by ... at the Medical College and Children,s Research Institute at ... the American Society of Hematology meeting Dec. 7, 2009, ...
(Date:12/6/2009)... and Treatment site www.sleeping-with-a-sleeping-disorder.com is asking ... or natural sleep aids from around the world ... good cause. The submissions will be compiled in ... by YOU, to be sold from the website ... 100% of the proceeds ,from sales of the ...
Breaking Medicine News(10 mins):Health News:Online Medical Supply Superstore Adds Cure Catheters to Product Mix 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 3Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2
... MichBio, the statewide trade,association for Michigan,s life sciences ... Caucus during its annual Expo &,Conference being held ... looks forward to working with the Biotechnology,Legislative Caucus ... to the,legislative process," said Stephen T. Rapundalo, Ph.D., ...
... Veteran Further Strengthens Company,s Sales and Service Team, ... largest,provider of business services to orthodontic and dental ... region sales. "Stuart,s many years of service ... to our company," said Chris Roussos, president and ...
... ARLINGTON HEIGHTS, Ill., Oct. 18 Think only,people with ... level of body satisfaction has no influence on whether ... surgery, according to a study,in October,s Plastic and Reconstructive ... of Plastic Surgeons (ASPS)., "This study shows the ...
... Oct. 18 Global Med Technologies(R),Inc. (OTC Bulletin ... announced today that its Wyndgate,Technologies(R) division ("Wyndgate") has ... by the U.S. Food and Drug Administration,(FDA). ElDorado ... U.S., pending 510(k),clearance by the FDA. ElDorado ...
... biomaterial, developed at the New Jersey Center for Biomaterials ... bench to field testing in record time. This achievement, ... is the enabling technology behind a coronary stent undergoing ... , Stents are tiny tubes inserted into diseased arteries ...
... Mayo Clinic has clarified the methods of diagnosis and ... disease of the brain and spinal cord that often ... vasculitis (PCNSV) can best be identified through a combination ... arteries), brain biopsy and other laboratory studies. , This ...
Other Medicine News:Health News:MichBio Announces Formation of Biotechnology Legislative Caucus 2Health News:Body Image Has Little Influence on Desire for Plastic Surgery, ASPS Study Reveals 2Health News:Body Image Has Little Influence on Desire for Plastic Surgery, ASPS Study Reveals 3Health News:Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA 2Health News:Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA 3Health News:Rutgers biomaterial debuts in clinical trials of new stent 2Health News:Rutgers biomaterial debuts in clinical trials of new stent 3Health News:Mayo Clinic clarifies diagnosis for serious blood vessel disease of brain and spinal cord 2Health News:Mayo Clinic clarifies diagnosis for serious blood vessel disease of brain and spinal cord 3
(Date:12/4/2009)... Inc. (NYSE Amex: PIP ), a biodefense company ... today the presentation of new data from the Company,s ... Antigen (rPA) based anthrax vaccine is structurally stable and ... and including 55 degrees C. The data were ...
(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), ... and chemical threats, announced today that the Company ... effectiveness of Valortim® in an inhalation anthrax model ... The data are being presented during an oral ...
(Date:12/4/2009)... 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ... that its subsidiary, Watson Laboratories, Inc.-Florida, filed an Abbreviated ... Drug Administration seeking approval to market its 8mg ramelteon ... by Takeda Pharmaceutical Company Limited. Watson,s 8mg ramelteon ...
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Janet Sartin Expands Line of Products That Reduce and Conceal Eye Puffiness and Fine Lines 51168 1Janet Sartin Expands Line of Products That Reduce and Conceal Eye Puffiness and Fine Lines 51168 2Janet Sartin Expands Line of Products That Reduce and Conceal Eye Puffiness and Fine Lines 51168 3ONRAD Announces New PACS Application Service Provider Model 51165 1ONRAD Announces New PACS Application Service Provider Model 51165 22 reproductive factors are important predictors of death from ovarian cancer 9184 12 reproductive factors are important predictors of death from ovarian cancer 9184 22 reproductive factors are important predictors of death from ovarian cancer 9184 3
... 04, 2007 /PRNewswire-FirstCall/ --,Genta Incorporated announced the ... trial of its marketed product, Ganite(R) (gallium,nitrate ... patients with relapsed or refractory non-Hodgkin's,lymphoma (NHL). ... meeting of,the American Society of Clinical Oncology ...
... Pertuzumab shows promising results in,advanced breast cancer ... BASEL, Switzerland, June 4, 2007-Early clinical results ... medicine pertuzumab, a HER,dimerisation inhibitor, show substantial ... breast cancer, when,combined with Herceptin. The study ...
Other Medicine Technology:Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5
... The CSV-1000CVA20/30 test face provides three contrast ... acuity from 20/16 to 20/100. This test is ... such as associated with contact lens evaluation or ... of the test provide the same contrast and ...
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
... Sample of Topics Covered: diagrams, ... tx's and differentials of a ... eyes, vision loss, pupillary abnormalities, ... infections, medications, cataracts, vision correction ...
Medicine Products: